Skip to content

Safety and Efficacy of Esketamine as an Adjuvant in Postoperative Analgesia after Thoracoscopic and Laparoscopic Esophagectomy: A Randomized Controlled Clinical Study

Safety and Efficacy of Esketamine as an Adjuvant in Postoperative Analgesia after Thoracoscopic and Laparoscopic Esophagectomy: A Randomized Controlled Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116111
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Control Group (Normal Saline Group) :Postoperative PCIA Analgesia (Sufentanil + Ondansetron + Normal Saline)
Experimental Group 1 (Esketamine 2mg/kg Group) :Postoperative PCIA Analgesia (Sufentanil + Ondansetron + Esketamine 2mg/kg)
Experimental Group 2 (Esketamine 3mg/kg Group) :Postoperative PCIA Analgesia (Sufentanil + Ondansetron + Esketamine 3mg/kg)
Experimental Group 3 (Esketamine 4mg/kg Group) :Postoperative PCIA Analgesia (Sufentanil + Ondansetron + Esketamine 4mg/kg)

Sponsors

Anhui Provincial Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 60 to 80 years old, gender not limited; 2.ASA Grade II - III; 3.BMI: 18-30 kg/m ² 4. The patient or (and) the family members request to undergo thoracoscopic and laparoscopic surgery for esophageal cancer under general anesthesia; 5. Be able to understand and voluntarily sign the informed consent form, and be willing to abide by the requirements of the trial protocol.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to or contraindicated to benzodiazepines, opioids, propofol, flumaciclib, naloxone, ketamine and their drug components; 2. Patients with severe heart, lung or kidney insufficiency, combined with multiple chronic diseases who cannot tolerate surgical anesthesia, as well as those with mental disorders; 3. Those with increased intracranial or intraocular pressure; 4. Those with a history of alcohol abuse, opioid allergy or abuse of such drugs; 5. Patients with uncontrolled severe hypertension; 6. Other circumstances that the researcher deems unsuitable for enrollment; 7. People who have had neurological diseases or undergone surgery recently.

Design outcomes

Primary

MeasureTime frame
VAS score (rest/cough) ;MMSE score ;

Secondary

MeasureTime frame
Postoperative PCIA pressing times ;Serum IL-6 level ;

Countries

China

Contacts

Public ContactTang Chaoliang

Anhui Provincial Cancer Hospital

chaolt@ustc.edu.cn+86 138 6677 7142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026